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i.org/1an enzyme upstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, to reduce
cholesterol biosynthesis. ETC-1002 monotherapy has demonstrated signiﬁcant reduction in
low-density lipoprotein cholesterol (LDL-C) compared with placebo in phase 2 studies. The
objective of this study was to compare the lipid-lowering efﬁcacy of ETC-1002 versus placebo
when added to ongoing statin therapy in patients with hypercholesterolemia. This phase 2b,
multicenter, double-blind trial (NCT02072161) randomized 134hypercholesterolemic patients
(LDL-C, 115 to220mg/dl) on stable backgroundstatin therapy to12weeksof add-on treatment
with ETC-1002 120mg, ETC-1002 180mg, or placebo. The primary efﬁcacy end point was the
percent change in calculated LDL-C from baseline to week 12. For LDL-C, the least-squares
mean percent change – standard error from baseline to week 12 was signiﬁcantly greater
withETC-1002 120mg (L17– 4%, p[ 0.0055) andETC-1002 180mg (L24– 4%, p<0.0001)
than placebo (L4– 4%). ETC-1002 also dose dependently reduced apolipoproteinB by 15% to
17%, nonehigh-density lipoprotein cholesterol by 14% to 17%, total cholesterol by 13% to 15%,
and LDL particle number by 17% to 21%. All these reductions in ETC-1002etreated cohorts
were signiﬁcantly greater than those with placebo. Rates of adverse events (AEs), muscle-
related AEs, and discontinuations for AEs with ETC-1002 were similar to placebo. In
conclusion, ETC-1002 120 mg or 180 mg added to stable statin therapy signiﬁcantly reduced
LDL-C compared to placebo and has a similar tolerability proﬁle.  2016 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;117:1928e1933)ETC-1002 (bempedoic acid) is an oral, once-daily therapy
that lowers low-density lipoprotein cholesterol (LDL-C) by
direct inhibition of adenosine triphosphate (ATP) citrate lyase,
an enzyme upstream of 3-hydroxy-3-methylglutaryl-coen-
zymeA reductase in the cholesterol biosynthesis pathway.This
inhibition leads to reduced cholesterol biosynthesis and
increased LDL receptor activity.1e3 The present phase 2b trial
(NCT02072161) evaluated whether add-on ETC-1002 would
lead to further reductions inLDL-C inpatientswith persistently
elevated LDL-C, despite stable, ongoing statin therapy.
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0.1016/j.amjcard.2016.03.043were on stable statin therapy were eligible for inclusion.
Stable statin therapy was deﬁned as use of atorvastatin (10 or
20 mg), simvastatin (5, 10, or 20 mg), rosuvastatin (5 or
10 mg), or pravastatin (10, 20, or 40 mg) for at least 3 months
before screening. Included participants had fasting, calculated
LDL-C levels from 115 to 220 mg/dl and a fasting triglyc-
eride level of 400 mg/dl after washout of lipid-regulating
agents other than the statins listed previously. Patients were
excluded if they had a history of clinically signiﬁcant car-
diovascular disease within 12 months of screening, including
but not limited to acute coronary syndromes, stroke, transient
ischemic attack, carotid or peripheral artery disease, or car-
diac arrhythmias; current clinically signiﬁcant cardiovascular
disease including decompensated heart failure, uncontrolled
hypertension, or cardiac arrhythmias; a history of liver or
muscle enzyme elevation that occurred during statin therapy
and resolved after statin discontinuation; type 1 diabetes or
uncontrolled type 2 diabetes; a history of long-term muscle
symptoms difﬁcult to differentiate from myalgia; current
muscle symptoms that may have been due to ongoing statin
therapy; uncontrolled hypothyroidism; liver or renal
dysfunction; gastrointestinal disorders affecting drug ab-
sorption; unexplained creatine kinase elevations; or use of
anticoagulants, colchicine, systemic corticosteroids, digoxin,
potent cytochrome P450 3A4 inhibitors or inducers, metfor-
min, or thiazolidinediones within 4 weeks of screening.ccess article
4.0/).
www.ajconline.org
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controlled, multicenter, phase 2b trial consisting of a
6-week screening and washout phase and a 12-week treat-
ment phase. Patients were randomized in a 1:1:1 ratio to
ETC-1002 120 mg, ETC-1002 180 mg, or matching placebo
once daily for 12 weeks in addition to ongoing statin ther-
apy. Participants were stratiﬁed by history of statin intoler-
ance, deﬁned as discontinuation of 1 statins at any dose
because of muscle-related symptoms. Patients supplied
background statin therapy from their usual source and
ingested study drug and statin once daily. Study visits
occurred every 2 weeks through week 8, with a ﬁnal visit at
week 12. Clinical laboratory assessments and basic fasting
lipid blood tests (total cholesterol, calculated LDL-C, high-
density lipoprotein cholesterol [HDL-C], and triglycerides)
were performed at screening and at all treatment-phase study
visits; all other fasting lipid and biomarker measurements
were performed at week 0 (day 1) and week 12. Adverse
events (AEs) were monitored throughout the study, begin-
ning with the ﬁrst screening visit, and were observed until
resolution or for 30 days after the last dose of study drug.
The primary efﬁcacy end point was the percent change in
calculated LDL-C from baseline to week 12 in patients
treated with ETC-1002 versus those treated with placebo.
Secondary efﬁcacy end points included the percent change
from baseline to week 12 in apolipoprotein B, noneHDL-C,
total cholesterol, LDL particle number, HDL-C, HDL par-
ticle number, apolipoprotein A-1, triglycerides, very-low-
density lipoprotein particle number, and high-sensitivity
C-reactive protein (CRP).
Safety assessments included reported or observed
treatment-emergent AEs, clinical laboratory tests (hematol-
ogy, serum chemistry, coagulation, urinalysis), physical
examination ﬁndings, vital sign measurements, electrocar-
diogram readings, weight, and ankle and waist circumfer-
ence measurements. AEs were coded using the Medical
Dictionary for Regulatory Activities version 16.1, and the
severity and relation to study drug was assessed by the
investigator. Muscle-related AEs were deﬁned as those from
the system organ class of musculoskeletal and connective
tissue disorders, except for those that were not obviously
muscle related. Terms included in the muscle-related AE
analysis were selected after database lock and before
unblinding; excluded terms were arthralgia, back pain,
bursitis, joint swelling, rotator cuff syndrome, and
tendonitis.
The planned sample size was 44 patients per treatment
group, which provided 90% power to detect a difference of
15% in the percent change in calculated LDL-C from baseline
to week 12 between at least 1 ETC-1002 treatment group and
the placebo group. This calculation was based on a 2-sided t
test at the 5% level of signiﬁcance and assumed a common
standard deviation of 20% and a dropout rate of 10%.
Efﬁcacy analyses were performed on the modiﬁed intent-
to-treat (mITT) population, which consisted of all random-
ized patients who received at least 1 dose of study drug, had
a baseline assessment, and at least 1 postbaseline assess-
ment, excluding any assessment taken more than 2 days
after a dose of study drug. Safety analyses were performed
on the safety population, which consisted of all randomized
patients who received at least 1 dose of study drug.For LDL-C, noneHDL-C, total cholesterol, HDL-C, and
triglycerides, baseline was deﬁned as the mean of the values
from the last screening visit (day 10 to 7) and day 1. For
all other efﬁcacy measurements, baseline was deﬁned as the
last value before the ﬁrst dose of study drug. Missing values
at week 12 were imputed using the last-observation-carried-
forward procedure.
An analysis of covariance was performed on the mITT
population to compare each dose of ETC-1002 with placebo
for the efﬁcacy end points and evaluated the effects of
treatment and history of statin intolerance with the baseline
value as a covariate. Least-square means and standard errors
were calculated for each treatment group, and differences in
least-square means, corresponding 2-sided 95% conﬁdence
intervals, and p values were obtained for the treatment
comparisons using Wilcoxon rank-sum tests.
Individual institutional review boards approved the
clinical study protocol and informed consent documents.
Written informed consent was obtained from all participants
before any study-related procedures.
Results
Of the 134 randomized patients, 115 (86%) completed
the trial and 19 patients (14%) discontinued early, most
often for withdrawn consent (Figure 1). Because 1 patient
who was randomized did not receive study drug, the safety
population included 133 patients. The number of patients
included in the mITT population varied according to the end
point assessed; 127 patients were included for the primary
efﬁcacy end point.
Baseline demographic and clinical characteristics were
similar among the treatment groups (Table 1). Overall, 10%
of the population reported a history of statin intolerance,
deﬁned as a previous discontinuation of at least 1 statin
medication because of muscle-related symptoms. The most
commonly used protocol-speciﬁed background statin
medication was simvastatin 20 mg (30%).
ETC-1002 120 and 180 mg added to stable statin ther-
apy reduced mean LDL-C signiﬁcantly more than placebo,
with the greatest reduction observed in patients who
received ETC-1002 180 mg (Table 2). The least-square
mean  standard error percent changes from baseline in
LDL-C were 4.2  4.2% with placebo, 17.3  4.0%
with ETC-1002 120 mg (p ¼ 0.0055 vs placebo),
and 24.3  4.2% with ETC-1002 180 mg (p <0.0001 vs
placebo; Figure 2). LDL-C reductions in the ETC-1002
treatment groups were signiﬁcantly greater than in the
placebo group by week 2 and remained signiﬁcantly
greater through week 12. The reduction in LDL-C was not
signiﬁcantly different in patients treated with ETC-1002
180 and 120 mg (difference in least-square mean percent
change, 7.0%; p ¼ 0.14).
Compared with placebo, treatment with ETC-1002 added
to statin therapy also signiﬁcantly reduced apolipoprotein B,
noneHDL-C, total cholesterol, and LDL particle number
(Table 2). Median CRP values were reduced by 22% with
ETC-1002 120 mg (p ¼ 0.26 vs placebo) and by 30% with
ETC-1002 180 mg (p ¼ 0.08 vs placebo). ETC-1002 did not
signiﬁcantly affect triglyceride levels or very-low-density
lipoprotein particle number. All treatment groups
Figure 1. Patient disposition. *One patient was randomized but discontinued before receiving study drug.
1930 The American Journal of Cardiology (www.ajconline.org)demonstrated slight decreases in HDL-C and apolipoprotein
A-1 levels, which were not signiﬁcantly different between
ETC-1002 and placebo. Both ETC-1002 treatment groups
demonstrated small increases in HDL particle number; the
difference in least-square mean percent change in HDL
particle number was signiﬁcant between ETC-1002 180 mg
and placebo (10.1% increase vs 1.6% decrease; p¼ 0.0004).
The overall incidence of AEs and drug-related AEs was
similar between ETC-1002 180 mg and placebo and lowest
with ETC-1002 120 mg (Table 3). The percent of patients
discontinuing because of AEs was not different between
placebo (3 patients; 1 with dizziness and headache, 1 with
cholelithiasis, 1 with constipation) and ETC-1002 180 mg (2
patients; 1 with rash, 1 with abdominal distention) or ETC-
1002 120 mg (no patients discontinued for AEs). Most AEs
were mild or moderate in severity. Serious AEs included 1
patient with noncardiac-related chest pain and 1 patient with
cholelithiasis in the placebo group and 1 patient with
ovarian adenoma who was treated with ETC-1002 180 mg;
all were determined unrelated to study drug. No speciﬁc
drug-related AE was reported by more than 1 patient in
either of the ETC-1002 treatment groups. Muscle-related
AEs were less frequent with ETC-1002 (2% to 5%) than
with placebo (13%) and caused no study discontinuations
(Table 3). Myalgia was reported in 2 placebo-treated pa-
tients, 1 patient treated with ETC-1002 120 mg, and no
patients treated with ETC-1002 180 mg.
No clinically important, dose-related trends in laboratory
changes were noted. No laboratory abnormality was
considered a serious AE or resulted in study drug discon-
tinuation. One patient treated with ETC-1002 180 mgexperienced a single increase in aspartate aminotransferase
>3 times the upper limit of normal (ULN) at week 12,
whereas alanine aminotransferase remained <2 times ULN;
there were no other instances of liver enzyme elevations >3
times ULN and no instances of creatine kinase elevations
>10 times ULN in any treatment group. No clinically
important differences were noted among the treatment
groups with respect to mean changes in physical examina-
tion ﬁndings, vital sign measurements, electrocardiogram
readings, weight, or ankle or waist circumference mea-
surements from baseline to week 12.
Discussion
In patients with elevated LDL-C levels despite stable
statin therapy, add-on treatment with ETC-1002 decreased
LDL-C levels, with both doses (120 and 180 mg) demon-
strating superior LDL-C lowering over placebo. In this
study, LDL-C was incrementally reduced up to 24% beyond
statin therapy in patients treated with ETC-1002. The pre-
sent trial is the ﬁrst study of the effects of ETC-1002 added
on to a range of stable background statin medications.
Analyses of the secondary efﬁcacy parameters apolipo-
protein B, noneHDL-C, total cholesterol, and LDL particle
number support the primary end point ﬁndings: both doses
of ETC-1002 signiﬁcantly reduced each of these parameters
compared with placebo. These results are consistent with
those from previous phase 2 trials in which these 4 measures
were signiﬁcantly reduced with ETC-1002 monotherapy
compared with placebo4 and compared with ezetimibe
monotherapy.5 Apolipoprotein B,6 noneHDL-C,7 and LDL
Table 1
Baseline demographic and clinical characteristics, safety population
Characteristic Placebo
(n ¼ 45)
ETC-1002
120 mg
(n ¼ 43)
ETC-1002
180 mg
(n ¼ 45)
Age (years) 56  10 59  9 57  10
Women 22 (49%) 26 (61%) 31 (69%)
White 37 (82%) 37 (86%) 37 (82%)
Not Hispanic/Latino 38 (84%) 33 (77%) 35 (78%)
NCEP ATP III Risk Category
Very high 6 (13%) 2 (5%) 1 (2%)
High 2 (4%) 3 (7%) 8 (18%)
Moderate 13 (29%) 23 (54%) 22 (49%)
Low 24 (53%) 15 (35%) 14 (31%)
LDL-C (mg/dl) 131  22 134  20 142  28
Total cholesterol
(mg/dl)
212  24 216  24 229  29
HDL-C (mg/dl) 54  14 55  15 55  14
Triglycerides (mg/dl) * 119 (82-159) 112 (88-178) 145 (122-196)
High-sensitivity
C-reactive protein
(mg/l)*†
1.8 (1.10-4.60) 1.8 (0.90-3.10) 1.8 (1.20-4.00)
Systolic blood pressure
(mm Hg)
126  12 128  11 129  14
Diastolic blood pressure
(mm Hg)
78  7 80  8 78  9
Weight (kg) 90  20 83  20 83  19
Body-mass index
(kg/m2)
31  6 30  6 30  6
History of statin
intolerancez
3 (7%) 6 (14%) 4 (9%)
Values are mean  SD, unless otherwise indicated. Baseline deﬁned as
the mean of the values from weeks 1 and 0, unless otherwise indicated.
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density
lipoprotein cholesterol; NCEP ATP III ¼ National Cholesterol Education
Program Adult Treatment Panel III.
* Values are median (interquartile range).
† For CRP, baseline deﬁned as the last value before the ﬁrst dose of study
drug; n ¼ 42 for ETC-1002 120 mg.
z History of statin intolerance was deﬁned as patient-reported discon-
tinuation of1 statin, at any dose, because of muscle-related symptoms. No
patients with a history of statin intolerance were experiencing statin-related
AEs at baseline.
Table 2
Percent changes in lipid and CRP levels from baseline to week 12, mITT
population
Placebo
(n ¼ 43)
ETC-1002
120 mg
(n ¼ 41)
ETC-1002
180 mg
(n ¼ 43)
Primary end point
LDL-C (mg/dl) -4.2  4.2 -17.3  4.0* -24.3  4.2†
Secondary end points
Apolipoprotein B (mg/dl) -5.5  3.4 -15.0  3.3z -17.2  3.4*
NoneHDL-C (mg/dl) -1.8  3.9 -14.3  3.7* -16.6  3.9*
Total cholesterol (mg/dl) -3.2  2.9 -12.8  2.7* -15.3  2.9*
LDL particle number (nmol/l) -2.3  4.3 -17.4  4.1* -21.3  4.3*
HDL-C (mg/dl) -2.0  2.7 -6.1  2.6 -4.0  2.7
HDL particle number (mmol/l) -1.6  2.8 4.0  2.7 10.1  2.8*
Apolipoprotein A-1 (mg/dl) -3.7  2.2 -2.0  2.1 -0.1  2.2
Triglycerides (mg/dl)x -3.0 (37) -4.8 (28) -9.1 (47)
VLDL particle number
(nmol/l)x
10.9 (76) 10.0 (67) -8.3 (91)
CRP (mg/l)x 0 (89) -21.8 (44) -29.8 (50)
Values are least-squares mean  standard error, unless otherwise indi-
cated. Baseline was deﬁned as the mean of the values from weeks 1 and
0 for LDL-C, noneHDL-C, total cholesterol, HDL-C, and triglycerides.
Baseline was deﬁned as the last value before the ﬁrst dose of study drug for
apolipoprotein B, LDL particle number, HDL particle number, apolipo-
protein A-1, VLDL particle number, and CRP.
CRP ¼ high-sensitivity C-reactive protein; HDL-C ¼ high-density
lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol;
mITT ¼ modiﬁed intent-to-treat; VLDL ¼ very-low-density lipoprotein.
* p < 0.01 vs placebo.
† p < 0.0001 vs placebo.
z p < 0.05 vs placebo.
x Values are median (interquartile range); p values vs placebo are from
Wilcoxon rank-sum test.
Figure 2. Mean percent change in LDL-C from baseline to week 12. These
data are from the modiﬁed intent-to-treat population. *p ¼ 0.0055 versus
placebo; †p <0.0001 versus placebo. Error bars represent standard error.
LS ¼ least-squares.
Preventive Cardiology/Incremental LDL-C Reduction With ETC-1002 1931particle number8 have all been shown to have stronger as-
sociations with the risk of cardiovascular events than
LDL-C. Thus, it is noteworthy that ETC-1002 signiﬁcantly
reduces apolipoprotein B, noneHDL-C, and LDL particle
number when used either as monotherapy or in combination
with ezetimibe or statins. Although there was no signiﬁcant
change in HDL-C, patients treated with ETC-1002 180 mg
demonstrated a modest but signiﬁcant increase in HDL
particle number, which has been shown to be inversely
associated with cardiovascular events in patients treated
with statin therapy.9 Previous phase 2 studies with ETC-
1002 monotherapy have demonstrated decreases in CRP
of 41%10 to 42%.11 In the present study, no incremental
reduction in CRP was observed for patients in the placebo
group (i.e., statin monotherapy), whereas the addition of
ETC-1002 120 or 180 mg to stable statin therapy nonsig-
niﬁcantly reduced CRP by 22% and 30% from baseline,
respectively.ETC-1002 was safe and well tolerated in the present
study, with a similar incidence of AEs between ETC-1002
180 mg and placebo and the lowest incidence observed in
patients treated with ETC-1002 120 mg. The incidence
of muscle-related AEs during the trial was low, and no
patients discontinued because of muscle-related AEs. This
Table 3
Treatment-emergent adverse events, safety population
Characteristic Placebo
(n ¼ 45)
ETC-1002
120 mg
(n ¼ 43)
ETC-1002
180 mg
(n ¼ 45)
Overview of AEs
Any AEs 28 (62%) 15 (35%) 28 (62%)
Serious AEs* 2 (4%) 0 1 (2%)
Study-drug related AEs† 9 (20%) 4 (9%) 8 (18%)
Discontinuation due to AEs 3 (7%) 0 2 (4%)
Most common AEsz
Constipation 2 (4%) 1 (2%) 0
Nausea 2 (4%) 1 (2%) 1 (2%)
Upper respiratory tract infection 1 (2%) 0 3 (7%)
Urinary tract infection 2 (4%) 3 (7%) 2 (4%)
Arthralgia 2 (4%) 0 0
Dizziness 2 (4%) 0 0
Headache 2 (4%) 1 (2%) 1 (2%)
Rash 0 1 (2%) 2 (4%)
Muscle-related AEsx 6 (13%) 2 (5%) 1 (2%)
Flank pain 0 1 (2%) 0
Muscle spasms 2 (4%) 0 1 (2%)
Muscular weakness 1 (2%) 0 0
Musculoskeletal pain 1 (2%) 0 0
Myalgia 2 (4%) 1 (2%) 0
Neck pain 1 (2%) 0 0
AE ¼ adverse event.
* Serious AEs included 1 patient with noncardiac chest pain and 1 patient
with cholelithiasis in the placebo group and 1 patient with ovarian adenoma
in the ETC-1002 180-mg group; all were determined to be not related to
study drug.
† AEs were considered drug related if relationship to study drug was
deemed possible, probable, or deﬁnite, or if relationship to study drug was
not recorded.
zMost common AEs were those occurring in 2 patients in any group,
excluding muscle-related AEs (which are shown separately, regardless of
frequency).
x Includes AEs from the system organ class musculoskeletal and con-
nective tissue disorders except for arthralgia, back pain, bursitis, joint
swelling, rotator cuff syndrome, and tendonitis.
1932 The American Journal of Cardiology (www.ajconline.org)observation of muscle safety with ETC-1002 is supported
by ﬁndings in previous phase 2 studies in patients with a
history of statin-associated muscle symptoms in which the
frequency of muscle-related AEs was not different with
ETC-1002 monotherapy compared with placebo11 or ezeti-
mibe monotherapy.5
Other nonstatin options used in conjunction with statins
for incremental LDL-C lowering include bile acid seques-
trants, which further reduce LDL-C by 10% to 20%,12 and
ezetimibe, which incrementally lowers LDL-C by 23% and
CRP by 10%.13 In studies of the newly approved proprotein
convertase subtilisin/kexin type 9 inhibitors added to statin
therapy, alirocumab has been shown to incrementally reduce
LDL-C by 48%14 to 72%15 from baseline, with no addi-
tional effect on CRP,16 and evolocumab has shown incre-
mental reductions of up to 66% from baseline.17 The
investigational cholesteryl ester transfer protein inhibitor
anacetrapib incrementally lowers LDL-C by 45% and has no
incremental effect on CRP when added to statins.18 It should
be noted that important differences in study designs, patient
inclusion criteria, baseline LDL-C and cardiovascular risklevels, length of treatment, and concomitant allowed medi-
cations in the referenced studies prevent direct comparisons
of results.
ETC-1002 inhibits ATP citrate lyase, an enzyme upstream
of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in the
cholesterol biosynthesis pathway.3 Because ETC-1002 and
statins target different enzymes in the cholesterol synthesis
cascade, the end result is overall decreased cholesterol syn-
thesis. The decreased cholesterol synthesis leads to upregu-
lation of LDL-receptors and subsequent reduction in the
circulating levels of LDL-C, suggesting that the mechanism
by which both drugs lower LDL-C is identical. Patients who
have an inadequate response on maximally tolerated statin
therapy represent an unmet need in the clinical management
of hypercholesterolemia. Furthermore, it is recognized that
residual cardiovascular risk remains in high-risk patients
despite optimized statin therapy and that new therapies are
needed to address this risk.19e21 This has inspired further
interest in the clinical use of nonstatin agents as add-on
therapy for incremental cholesterol reduction and incre-
mental beneﬁt on long-term cardiovascular outcomes. Recent
clinical trial evidence with ezetimibe supports the concept
that incremental LDL-C lowering in the long-term, beyond
statin therapy, is associated with improved cardiovascular
outcomes.22,23 The present study was designed to reﬂect a
typical clinical scenario in which a second lipid-modifying
drug is added to ongoing low- or moderate-intensity statin
therapy to achieve additional LDL-C lowering, and the efﬁ-
cacy and safety ﬁndings in this short-term study demonstrate
a potentially promising beneﬁt-risk proﬁle for ETC-1002 in
these conditions.
We acknowledge the following study limitations. As a
phase 2 trial, the sample size was relatively small and the
duration of treatment was only 12 weeks. The safety and
efﬁcacy demonstrated in the present study support further
evaluation of ETC-1002 as add-on to statins in larger clin-
ical trials in the future. Also, despite the randomized trial
design, there were some differences in baseline character-
istics among the treatment groups, including gender, level of
cardiovascular risk, and levels of LDL-C and triglycerides.
In patients with elevated LDL-C levels despite stable
statin therapy, the addition of ETC-1002 120 or 180 mg
daily produces signiﬁcant and clinically relevant incre-
mental LDL-C lowering and is well tolerated. These results
indicate that adding once-daily oral ETC-1002 to stable
statin therapy may be a useful clinical strategy in the
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